← Back

Boundless Bio, Inc. Common Stock

Boundless Bio, Inc., a clinical-stage oncology company, develops interrogating extrachromosomal DNA (ecDNA) directed therapies for treating patients with oncogene amplified cancers. Its lead product candidate is BBI-940, an ecDNA-directed therapeutic candidate (ecDTx) that is in Phase 1/2 clinical trial in patients with estrogen receptor positive and human epidermal growth factor receptor 2 negative breast cancer, as well as patients with triple-negative breast cancer luminal androgen receptor subtype. The company was formerly known as Pretzel Therapeutics, Inc. and changed its name to Boundless Bio, Inc. in July 2019. Boundless Bio, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

Price · split & dividend adjusted
News & notes moving BOLD
BOLD

Halper Sadeh LLC Investigates Fairness of Deals for DAN, ESI, NUVL, BOLD Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating whether the proposed transactions involving Dana Incorporated, Element Solutions Inc, Nuvalent Inc, and Boundless Bio Inc are fair to their shareholders. The firm is examining Dana's sale to Eaton Corporation, where Dana shareholders would own approximately 49.9% of the combined company, and Element Solutions' sale to Solstice Advanced Materials for $10.00 in cash and 0.500 shares of Solstice common stock per Element share, with Element shareholders expected to own about 44% of the combined entity. It is also looking into Nuvalent's sale to GSK for $124.00 per share in cash and Boundless Bio's merger with Serapha Bio, where Boundless Bio shareholders would hold roughly 3.7% of the combined company. Halper Sadeh may seek increased consideration or additional disclosures on behalf of shareholders, who can contact the firm at no cost to discuss their legal rights.
BOLD DAN ESI NUVL
GlobeNewswire·51dRead more ▾
BOLD▼

Halper Sadeh LLC Investigates BOLD and NDRA Mergers for Shareholder Fairness

Halper Sadeh LLC, an investor rights law firm, is investigating Boundless Bio and ENDRA Life Sciences over their proposed mergers, citing concerns that shareholders may not be receiving fair deals. The firm says insiders could obtain substantial financial benefits not available to ordinary shareholders, and the transactions may contain terms that limit superior competing offers. Boundless Bio shareholders are expected to own approximately 3.7% of the combined company after its merger with Serapha Bio, while ENDRA shareholders would hold about 3% following its merger with Noble Africa. Halper Sadeh may seek increased consideration or additional disclosures on behalf of shareholders, and encourages them to contact the firm at no cost to discuss their rights.
BOLD ▼NDRA ▼
GlobeNewswire·55dRead more ▾
Biotech & Genomic Medicine▲

Boundless Bio, Monopar, Galectin Lead Biotech Gainers on Pipeline Advances

Several biotech stocks surged on Tuesday, led by Boundless Bio which agreed to an all-stock merger with privately held Serapha Bio. Boundless Bio expects to declare a cash dividend to pre-merger stockholders before the deal closes in the fourth quarter of 2026, after which the combined company will operate as Serapha Bio and trade on Nasdaq under the ticker AATD. Monopar Therapeutics rose over 19% with its New Drug Application for ALXN1840 in Wilson disease on track for mid-2026 submission to the FDA. Galectin Therapeutics gained over 11% after reaching an agreement with the FDA on key elements of its planned Phase 3 program for Belapectin in MASH cirrhosis with portal hypertension, with the final protocol expected in the third quarter of 2026. Other notable movers included Jade Biosciences, up nearly 13% amid progress in its autoimmune pipeline, and Treace Medical Concepts, up almost 12% following the first surgical use of its HyperPlate XM implant.
BOLD ▲GALT ▲JBIO ▲MNPR ▲TMCI ▲
Biotech & Genomic Medicine ▲
RTTNews·64dRead more ▾
Biotech & Genomic Medicine▲

NeOnc, Boundless Bio, Backblaze, and HeartSciences announce major catalysts

Several emerging companies are approaching significant inflection points. NeOnc Technologies received Investigational New Drug authorization from the Department of Health–Abu Dhabi for its NEO100 program, covering adult Phase 1 through Phase 2 studies and establishing a pathway for pediatric development in high-grade gliomas, with a Phase 2a readout expected by the end of July 2026. Boundless Bio announced a proposed merger with privately held Serapha Bio, creating a publicly traded company focused on gene-editing therapies for Alpha-1 Antitrypsin Deficiency, backed by approximately $230 million in committed financing from a syndicate led by RTW Investments and RA Capital Management. Backblaze signed a five-year, multi-exabyte data storage agreement valued at approximately $335 million with AI cloud infrastructure provider CoreWeave, positioning Backblaze as a key storage provider for portions of CoreWeave's managed storage infrastructure. HeartSciences announced a proposed business combination with Fortitude Mining Holdings, a digital asset mining platform focused primarily on Zcash, with existing Fortitude owner Digital Currency Group expected to hold approximately 95% of the combined company upon closing.
BLZE ▲BOLD ▲HSCS NTHI ▲
Biotech & Genomic Medicine ▲Artificial Intelligence ▲
GlobeNewswire·64dRead more ▾
© 2026 MarketDXAsset